Amgen Reports Safety & Efficacy Results of Repatha (evolocumab) in OSLER-1 Five-Year Extension Study

 Amgen Reports Safety & Efficacy Results of Repatha (evolocumab) in OSLER-1 Five-Year Extension Study

Amgen Reports Safety & Efficacy Results of Repatha (evolocumab) in OSLER-1 Five-Year Extension Study

Shots:

  • The OSLER-1 (Open-Label Study of Long-TERm Evaluation Against LDL-C) study involves assessing of Repatha (420 mg) + SoC or SoC alone in patients with hypercholesterolemia in ratio (2:1) across 192 sites in 18 countries
  • OSLER-1 (N≤ 1324) study results: reduction in mean LDL-C @1/2/3/4/5yrs. (59%, 56%, 57%, 56%, 56%). Another study GOULD is practiced in patients with ASCVD to demonstrate levels of LDL-C in US over category: currently receiving a PCSK9i antibody, no PCSK9i and LDL-C 70-99 mg/dL, & no PCSK9i and LDL-C ≥ 100 mg/dL
  • GOULD study demonstrated underutilization of LDL-C lowering treatments in high risk CV events patients and awareness of treatment goals
  • Repatha is a mAb used for inhibiting PCSK9 (proprotein convertase subtilisin/kexin type 9) and is currently approved in > 60 countries including the US, Japan, Canada

Click here to read full press release/ article | Ref: Amgen| Image: USA Today

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post